Of particular interest, NGF/TRKA signaling has been shown to be constitutively active and play an important role against imatinib through activation of the Akt pathway in BCR-ABL positive CML cells 23. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.